Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in moderate to severe acne vulgaris
NCT01498874Phase 2Completed
- Sponsor
- XOMA
- Start
- Dec 2011
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gevokizumab in acne vulgaris, sponsored by XOMA. Started Dec 2011; status: completed.
02
Drugs
gevokizumab
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT01498874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01498874.